Uncategorized

Former ZimVie CFO Richard Heppenstall fills the vacancy created by the departure of Leo Greenstein, who is leaving Carlsmed to pursue other professional interests.

Robert Hunter will focus on UnitedHealthcare’s “modernization agenda” in the new role. It’s the latest in a slew of leadership changes at UnitedHealth as the company works to restore its image.

The venture capital firm expects to launch up to eight new medtech ventures over the next five years.

Citing market uncertainty, the smart ring maker plans to delay a public offering that it had expected to raise up to $2.2 billion.

Newly released CMS data gives the market its first comprehensive look at how insurers are adapting to continued pressure in the privatized Medicare program. A press release stressing “stability” didn’t soften the blow.

Roche’s anti-myostatin therapy emugrobart is unlikely to elicit meaningful weight loss, according to an interim mid-stage analysis, prompting the pharma to return the asset rights to its subsidiary Chugai Pharmaceutical.

The U.S. is on the brink of a healthcare workforce crisis, according to a new report from healthcare education company Covista. But it’s not too late to try to mitigate the impact.

The results are nevertheless “unprecedented,” UniQure executives said on an investor call Tuesday, emphasizing that the updated natural history database used as the control group for the Phase 1/2 study of AMT-130 underestimates disease progression.

The all-stock deal gives Summit Therapeutics enough money to see through Phase 3 trials for the PD-1/VEGF bispecific ivonescimab—but keeps the asset fully in-house without giving up licensing rights.

Investors looking for more transformative business development at Novo will have to wait, but a new partnership with China’s Hengrui Pharma adds a new weekly oral option to the Danish pharma’s early pipeline.